Quadrature Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Quadrature Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.06M	Buy	16,851 +9,055	+116%	+$1.98M	0.03%	321
2026 Q1	$1.47M	Buy	7,796 +2,208	+40%	+$386K	0.02%	462
2025 Q4	$950K	Buy	+5,588	New	+$857K	0.01%	532
2016 Q3	–	Sell	-25,154	Closed	-$3.56M	–	644
2016 Q2	$3.56M	Buy	+25,154	New	+$3.71M	0.26%	96

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Quadrature Capital's JAZZ Position: Q2 2026 in Review

Quadrature Capital increased its Jazz Pharmaceuticals (JAZZ) stake by 116% in Q2 2026, buying an estimated $1.98M and bringing the position to 16,851 shares worth $4.06M. The position accounts for 0.03% of the portfolio, ranked #321.

Quadrature Capital first reported a position in JAZZ in Q2 2016 and has held it in 4 quarters since. 647 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

Quadrature Capital held 16,851 shares of Jazz Pharmaceuticals worth $4.06M as of Q2 2026.
Quadrature Capital bought 9,055 Jazz Pharmaceuticals shares in Q2 2026, an estimated $1.98M.
Jazz Pharmaceuticals made up 0.03% of Quadrature Capital's portfolio in Q2 2026, its #321 holding.
Quadrature Capital first reported a position in Jazz Pharmaceuticals in Q2 2016 and has held it in 4 quarters since.
647 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.